Q32 Bio Inc

1. 1

   Election of Class II Directors

   ManagementBoard: FOR

   Elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to serve three-year terms until 2029.

2. 2

   Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as Q32 Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

   More detail

   This management proposal requests that stockholders ratify the audit committee’s selection of Ernst & Young LLP (EY) as the company’s independent registered public accounting firm for the 2026 fiscal year. Management frames the vote as a corporate governance best practice rather than a legal requirement and indicates that the audit committee retains discretion to change auditors regardless of the shareholder vote. Background context includes EY’s service since March 2024 and pre-merger service to Legacy Q32 since 2020; the company disclosed EY fees for audit, audit-related and tax services for 2024 and 2025, and described an audit committee pre-approval policy for audit and non-audit services. The Board recommends a vote FOR, noting that ratification provides shareholder input on the selection — and signals approval of EY’s independence and performance — while also preserving the committee’s ability to act if concerns arise. Material considerations for analysts include the total fees paid to EY (modest relative to company size), the existence of non-audit fees (audit-related and tax services), and the board’s explicit contingency that it may replace EY irrespective of ratification, which together inform assessments of auditor independence and potential audit quality issues.

3. 3

   Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory approval of compensation paid to the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This management proposal seeks a non-binding advisory endorsement (Say-on-Pay) of the company’s executive compensation program as disclosed in the proxy. Management argues that the compensation programs are designed to attract and retain qualified executives, align executives’ interests with stockholders through a mix of base salary, annual performance-based cash bonuses, and long-term equity incentives, and that the company’s compensation committee used an independent consultant (Aon) to benchmark pay. The Board recommends a vote FOR. Analysts should weigh factors including recent option repricing, the size and structure of equity awards and cash incentives, change-in-control protections, and the link between pay and performance metrics disclosed in the Pay Versus Performance tables. Because the vote is advisory, it carries no binding effect, but a negative outcome would likely prompt management to revisit compensation practices given the company’s stated intent to consider shareholder feedback.

Upcoming shareholder meetings at Q32 Bio Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Q32 Bio Inc 2026 annual meeting?

Q32 Bio Inc (QTTB) holds its 2026 annual shareholder meeting on Friday, June 12, 2026.

What is the record date for the Q32 Bio Inc 2026 meeting?

The record date for the Q32 Bio Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Q32 Bio Inc's 2026 meeting?

The board is presenting 3 director nominees at the Q32 Bio Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Q32 Bio Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Q32 Bio Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.